Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
The standardization and clinical validation of the measurement of beta-amyloid(1-42) (Abeta42) in cerebrospinal fluid (CSF), plasma and urine is described using a commercially available sandwich-type ELISA with 21F12 and 3D6 as monoclonal antibodies. The INNOTEST beta-amyloid(1-42) allows the specific and reliable measurement of(1-42) amyloid peptides in CSF and plasma. The Abeta42 concentrations in serum and urine were below the detection limit. In plasma, no differences were found in Abeta42 levels between controls and patients with different neurodegenerative disorders (Alzheimer's disease (AD), Lewy body disease (LBD), others). In contrast, CSF-Abeta42 concentrations were lower in AD and LBD patients as compared to controls. No correlation was found in AD patients between CSF and plasma concentrations of Abeta42 or between CSF Abeta42 levels and blood-brain-barrier function. The quantitative outcome of the test is in part dependent on confounding factors such as tube type, freeze/thaw cycles, temperature of incubation, standard preparation protocol, and antibody selection. Notwithstanding these aspects, it emerged that Abeta42 is a useful biochemical marker for the diagnosis of AD patients, but there is a need for an international Abeta standard, a universally accepted protocol for CSF preparation, and a thorough evaluation of assay performance in function of the boundary conditions.
Vanderstichele
H
H
Innogenetics NV, Ghent, Belgium. hugovdr@innogenetics.be
Van Kerschaver
E
E
Hesse
C
C
Davidsson
P
P
Buyse
M A
MA
Andreasen
N
N
Minthon
L
L
Wallin
A
A
Blennow
K
K
Vanmechelen
E
E
D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid*; D016229:Amyloid beta-Peptides / Q000097:blood* / Q000134:cerebrospinal fluid*; D004797:Enzyme-Linked Immunosorbent Assay / Q000592:standards*; D006801:Humans; D012015:Reference Standards; D013048:Specimen Handling
D016229:Amyloid beta-Peptides